Metyrosine Disease Interactions

Extrapyramidal symptoms (EPS) have occurred in approximately 10% of patients receiving metyrosine. EPS include drooling, speech difficulty, and tremor. Trismus and parkinsonian syndrome have been reported. Therapy with metyrosine should be administered cautiously in patients with or predisposition to EPS or Parkinson's disease. Dosage reduction or discontinuation of metyrosine may be necessary.

Anxiety, excitability, and psychic disturbances such as hallucinations, disorientation/confusion, emotional instability, and depression have occurred in patients receiving metyrosine. Therapy with metyrosine should be administered cautiously in patients with psychiatric and/or emotional disorders. Dosage reduction may be appropriate. Clinical monitoring of emotional and psychiatric status is recommended.

Metyrosine is primarily eliminated by the kidney. The serum concentration of metyrosine may be increased in patients with renal impairment. Therapy with metyrosine should be administered cautiously in patient with compromised renal function. Clinical monitoring of renal function is recommended.